Company Profile

Accurius Therapeutics Inc
Profile last edited on: 3/11/2024      CAGE: -----      UEI: QDZQGEE1TAX3

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

213 East Street
Lexington, MA 02420
   (857) 260-8126
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

Accurius Therapeutics Inc mission is to fundamentally transform cancer treatment and improve outcomes for cancer patients by developing a first-of-a-kind inhalable agent that is designed to be a safe and effective treatment for mNSCLC and other cancers metastatic to the lung. Firm have designed an engineered oncolytic virus based on the Influenza A virus (eIAV) that selectively infects and destroys cancer cells while sparing healthy cells and activates the body’s own anti-tumor immune response. There are more than 230,000 new cases of lung cancer and over 130,000 deaths due to lung cancer each year in the U.S. Approximately 120,000 people each year will present with metastatic Non-Small Cell Lung Cancer (mNSCLC) for the first time, and only 7% of these patients will survive five years or more. We think the treatment futility surrounding this disease is unacceptable and we’re focused on changing it. This treatment is expected to improve overall survival rates for the metastatic NSCLC patient population as well for the 50,000 patients each year with different tumor types that have their cancer metastasize to the lung.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Mallikarjun Srivatsan -- CEO and Co-founder

  Christian Mandl -- Co-Founder And Chief Scientific Officer

  Kirk Mundy -- Chief Commercial Officer

  Dmitriy Zamarin -- Co-Founder And Chief Medical Officer

Company News

There are no news available.